Європейський Союз - ісландська - EMA (European Medicines Agency)

novartis europharm limited - ceritinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - zykadia er ætlað til meðferðar hjá fullorðnum sjúklingum með lungnakrabbamein (anaplastic lymphoma kinase (alk)) sem hefur áður fengið meðferð með crizotinibi.

Європейський Союз - ісландська - EMA (European Medicines Agency)

roche registration gmbh - alectinib hýdróklóríð - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - alecensa sem einlyfjameðferð er ætlað til fyrstu meðferðar hjá fullorðnum sjúklingum með lungnakrabbamein (anaplastic lymphoma kinase (alk)) sem ekki er lungnakrabbamein (nsclc). alecensa eitt og sér er ætlað fyrir meðferð fullorðinn sjúklinga með t‑jákvæð háþróaður nsclc áður meðhöndluð með crizotinib.

Європейський Союз - ісландська - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Європейський Союз - ісландська - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Європейський Союз - ісландська - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Європейський Союз - ісландська - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Ісландія - ісландська - LYFJASTOFNUN (Icelandic Medicines Agency)

williams & halls ehf - acidum ibandronicum mónónatríum - stungulyf, lausn - 3 mg

Європейський Союз - ісландська - EMA (European Medicines Agency)

zoetis belgium sa - lifandi aróa geni eytt escherichia coli, tegund 078, stofn ec34195 - Ónæmislyf fyrir aves, lifandi bakteríu bóluefni - chicken; turkeys - fyrir virk bólusetningar af neitt grill hænur og framtíð lag / ræktendur í röð til að draga úr jörðu og sár (gollurshússbólga, perihepatitis, airsacculitis) í tengslum við kólígerlar serotype o78.

Європейський Союз - ісландська - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - skal læknir hafa tyrklandi herpesveiru, álag vhvt013-69, lifandi - Ónæmislyf fyrir aves, innlendum fugl, Ónæmislyf - embryonated eggs; chicken - fyrir virk bólusetningar hænur:til að koma í veg fyrir dauða og til að draga úr klínískum merki og sár af völdum bursal sjúkdómur. til að draga úr jörðu klínískum merki og sár marek er sjúkdómur.

Європейський Союз - ісландська - EMA (European Medicines Agency)

intervet international b.v. - klefi-í tengslum lifandi skal læknir hafa tyrklandi herpesveiru (álag hvp360), tjá samruna prótín nd veirunni og vp2 prótín ibd veira - fugla herpesvírusinn (marek er sjúkdómur) + fugla smitandi bursal sjúkdómur veira (gumboro sjúkdómur) + newcastle sjúkdómur veira/paramyxovirus - chicken; embryonated chicken eggs - for active immunisation of one-day-old chicks or 18-19-day-old embryonated chicken eggs:to reduce mortality and clinical signs caused by newcastle disease (nd) virus,to prevent mortality and to reduce clinical signs and lesions caused by infectious bursal disease (ibd) virus,to reduce mortality, clinical signs and lesions caused by marek’s disease (md) virus.